Results 241 to 250 of about 677,625 (318)

Iron in breastfed infants and behavior at 3 years: a randomized trial. [PDF]

Sci Rep
Svensson LK, Chmielewski G, Domellöf M, Konarska Z, Pieścik-Lech M, Späth C, Szajewska H, Chmielewska A.   +7 more
europepmc   +1 more source

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. [PDF]

Eur J Neurol
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree BAC, Ansari S, Meier DP, Karlsson G, Rouyrre N, Giovannoni G.   +11 more
europepmc   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G. Johnson, Elena Peeva, Michael S. Vincent, Valerie M. Clerin   +11 more
wiley   +1 more source

The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID. [PDF]

Ment Health Clin
Pucci SL, Veide A, Pierce H, Kaminski D.
europepmc   +1 more source

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Ismahaan Abdisalaam, Rianne Rijneveld, Erica S. Klaassen, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Benthe Freyee, Karin Platenkamp, Mariette E. van Poelgeest, Robert Rissmann, Martijn B. A. van Doorn, Tessa Niemeyer – van der Kolk   +15 more
wiley   +1 more source

Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis. [PDF]

Eur J Neurol
Duarte GS, Machado TLGN, Rodrigues FB, Conceção I, Pareyson D, da Costa JNMPG, Task Force of the EAN/PNS Joint Guideline for the Management of Neurological Manifestations in Hereditary Transthyretin Amyloidosis.   +6 more
europepmc   +1 more source

Lowering salivary pH with sugar‐containing gum augments salivary nitrite production and blood pressure reduction with dietary nitrate (beetroot juice)

British Journal of Clinical Pharmacology, EarlyView.
Acutely lowering salivary pH (with sugar‐containing acidic gum vs. sugar‐free gum) augments salivary nitrate reduction to nitrite, plasma nitrite concentration, and blood pressure lowering with dietary nitrate. Modifying salivary pH reveals a mechanism by which the nitrate‐nitrite‐NO pathway may be upregulated/inhibited, with potential for other ...
Andrew J. Webb, Harriet Clift, Callum Hill, Nur Mousa, Navanithan Arun Jayaraj, Jasmine Quraishi, Charlotte E. Mills, Kevin O'Gallagher   +7 more
wiley   +1 more source

Efficacy of Levetiracetam in Patients With Pediatric Epilepsy: A Systematic Review and Meta-Analysis. [PDF]

Neurology
Balestrini S, Puliti D, Lombardini M, Bettiol A, Gasparini S, Lomonaco M, Presotto EM, Dalmazio Tarantino EP, De Masi S, Guerrini R.   +9 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source